Gland Pharma Shares Rise by 2.10% in Today's Session
The movement in Gland Pharma's stock price reflects ongoing market dynamics and company-specific financial performance. Investors are likely weighing these factors as they assess the stock's potential.
Alpha Desk
May 14, 2025 / 15:15 IST
DisclaimerThis is an AI-assisted live blog with updates sourced from multiple news outlets and agenciesDisclaimer
Shares of Gland Pharma experienced a rise of 2.10% during today's session, with the price reaching Rs 1,463.30. This movement is noteworthy for investors tracking the pharmaceutical sector and the NIFTY MIDCAP 150 index, where Gland Pharma is a constituent.
The NIFTY MIDCAP 150 includes Gland Pharma, reflecting its significance among mid-sized companies. Analyzing the company's financial performance can provide context to the stock's behavior. According to Moneycontrol analysis, the sentiment on May 12, 2025, was bearish.
Financial Performance
Recent financial data reveals consistent revenue and net profit figures for Gland Pharma. Here’s a snapshot of the company’s financial performance:
Analyzing the income statement provides further insights into Gland Pharma's financial health. Key figures include:
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Sales
4,167
3,616
4,400
3,462
2,633
Other Income
166
240
223
134
139
Total Income
4,334
3,856
4,624
3,597
2,772
Total Expenditure
2,920
2,801
3,000
2,259
1,772
EBIT
1,413
1,055
1,624
1,338
1,000
Interest
7
7
5
3
7
Tax
362
272
406
337
220
Net Profit
1,043
775
1,212
997
772
Quarterly Performance
A look at the quarterly numbers provides a more granular view of Gland Pharma's income statement:
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sales
1,010
1,062
1,012
1,174
1,097
Other Income
65
57
48
46
43
Total Income
1,075
1,120
1,060
1,221
1,141
Total Expenditure
663
740
759
784
768
EBIT
412
379
301
437
372
Interest
18
0
0
4
0
Tax
99
98
77
111
94
Net Profit
295
281
222
321
276
Cash Flow
Cash flow details reveal the following trends:
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Operating Activities
1,135
367
791
604
700
Investing Activities
-2,923
1,208
-1,010
-1,524
-766
Financing Activities
-7
14
34
1,238
-6
Others
6
3
3
3
5
Net Cash Flow
-1,789
1,594
-180
322
-66
Balance Sheet
The balance sheet provides an overview of Gland Pharma's assets and liabilities:
Equities & Liabilities
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Share Capital
16
16
16
16
15
Reserves & Surplus
8,977
7,935
7,141
5,886
3,630
Current Liabilities
414
730
581
512
359
Other Liabilities
132
91
94
80
80
Total Liabilities
9,541
8,773
7,834
6,496
4,086
Assets
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Fixed Assets
1,813
1,747
1,692
1,292
1,156
Current Assets
4,571
6,888
5,844
5,123
2,846
Other Assets
3,156
137
296
80
83
Total Assets
9,541
8,773
7,834
6,496
4,086
Other Info
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Contingent Liabilities
100
128
124
219
134
The movement in Gland Pharma's stock price reflects ongoing market dynamics and company-specific financial performance. Investors are likely weighing these factors as they assess the stock's potential.
